Fig. 9.

Ivermectin affects energy metabolism for its anticancer efficiency through targeting PFKP, IDH2, IDH3B, ND2, ND5, CYTB, UQCRH, MCT1, and MCT4 at the mRNA levels analyzed with qPCR. a–f EOC cells adding ivermectin (10 μM, 20 μM, and 30 μM) and control cell lines (within 0.1% DMSO) were verified by RT-PCR after treatment to identify energy metabolism enzymes and lactate shuttle (MCT1 and MCT2) mRNA expressions (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001. PFKP, phosphofructokinase platelet; IDH2, isocitrate dehydrogenase (NADP(+)) 2; IDH3B, isocitrate dehydrogenase (NAD(+)) 3 noncatalytic subunit beta; ND2, mitochondrially encoded NADH dehydrogenase 2; ND5, mitochondrially encoded NADH dehydrogenase 5; UQCRH, ubiquinol-cytochrome c reductase hinge protein; MCT1, solute carrier family 16 member 1; MCT4, solute carrier family 16 member 4; EOC, epithelial ovarian carcinoma; CYTB, mitochondrially encoded cytochrome b; DMSO, dimethyl sulfoxide; qRT-PCR, quantitative real-time PCR